Beset by challenges with its Alzheimer’s disease drug, Biogen pivots
May 03, 2022 at 12:47 PM EDT
The company plans to let go of its CEO and scrap commercial plans for its controversial Alzheimer’s disease drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.